Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
暂无分享,去创建一个
[1] M. Milhollen,et al. Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues , 2011, The Journal of Biological Chemistry.
[2] R. Orlowski,et al. A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies , 2009, Clinical Cancer Research.
[3] M. Monden,et al. Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[5] I. Ota,et al. A Proteolytic Pathway That Recognizes Ubiquitin as a Degradation Signal (*) , 1995, The Journal of Biological Chemistry.
[6] A. Isacchi,et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. , 2013, Nature chemical biology.
[7] A. Miyauchi,et al. Increased Expression of Valosin-Containing Protein (p97) Is Correlated With Disease Recurrence in Follicular Thyroid Cancer , 2005, Annals of Surgical Oncology.
[8] L. Bruhn,et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.
[9] Angelika Amon,et al. Aneuploidy Affects Proliferation and Spontaneous Immortalization in Mammalian Cells , 2008, Science.
[10] P. Kloetzel,et al. Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian Proteasomes* , 2003, Journal of Biological Chemistry.
[11] S. Lindquist,et al. HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.
[12] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[13] K. Lindsten,et al. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. , 2001, Molecular cell.
[14] R. Deshaies,et al. Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase , 2013, ChemMedChem.
[15] R. Deshaies,et al. Cdc48/p97 mediates UV-dependent turnover of RNA Pol II. , 2011, Molecular cell.
[16] D. Ron,et al. Uncoupling Proteostasis and Development in Vitro with a Small Molecule Inhibitor of the Pancreatic Endoplasmic Reticulum Kinase, PERK* , 2012, The Journal of Biological Chemistry.
[17] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[18] R. Silverman,et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule , 2012, Proceedings of the National Academy of Sciences.
[19] M. Correia,et al. Liver Cytochrome P450 3A Endoplasmic Reticulum-associated Degradation , 2010, Journal of Biological Chemistry.
[20] Michael L. Wang,et al. Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma , 2013, Clinical Cancer Research.
[21] S. Gygi,et al. Quantitative proteomic analysis reveals posttranslational responses to aneuploidy in yeast , 2014, eLife.
[22] J. Fahy,et al. 7 The Vinca Alkaloids , 2005 .
[23] M. Bug,et al. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system , 2012, Nature Cell Biology.
[24] Dan Garza,et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS , 2007, Nature.
[25] J. Taylor,et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD , 2010, Autophagy.
[26] P. Cascio,et al. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors , 2012, Journal of leukocyte biology.
[27] C. Crews,et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] F. Delom,et al. P97/CDC-48: proteostasis control in tumor cell biology. , 2013, Cancer letters.
[29] K. Anderson,et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib , 2005, Nature Methods.
[30] S. Schreiber,et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] Suzanne F. Jones,et al. A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.
[32] A. Koong,et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. , 2011, Blood.
[33] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[34] Andreas Martin,et al. Conformational switching of the 26S proteasome enables substrate degradation , 2013, Nature Structural &Molecular Biology.
[35] N. Yoshimura,et al. Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa , 2014, Scientific Reports.
[36] J. Weissman,et al. Road to Ruin: Targeting Proteins for Degradation in the Endoplasmic Reticulum , 2011, Science.
[37] M. Fromont-Racine,et al. Cdc48-associated complex bound to 60S particles is required for the clearance of aberrant translation products , 2013, Proceedings of the National Academy of Sciences.
[38] Michael L. Wang,et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. , 2013, Blood.
[39] K. Lindsten,et al. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells , 2000, Nature Biotechnology.
[40] Maitreya J. Dunham,et al. Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast , 2007, Science.
[41] B. le Bail,et al. Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death , 2012, Molecular Cancer Therapeutics.
[42] M. Imoto,et al. Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. , 2012, ACS chemical biology.
[43] R. Deshaies,et al. p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition , 2013, bioRxiv.
[44] R. Deshaies,et al. Cdc48/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome , 2013, eLife.
[45] J. Adams. The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.
[46] Donna D. Zhang,et al. Functional Chromatography Reveals Three Natural Products that Target the Same Protein with Distinct Mechanisms of Action , 2014, Chembiochem : a European journal of chemical biology.
[47] Osamu Ishikawa,et al. Increased Expression of Valosin-Containing Protein (p97) is Associated With Lymph Node Metastasis and Prognosis of Pancreatic Ductal Adenocarcinoma , 2004, Annals of Surgical Oncology.
[48] B. Weaver,et al. Does aneuploidy cause cancer? , 2006, Current opinion in cell biology.
[49] M. Beksac,et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. , 2014, The Lancet. Oncology.
[50] D. Durocher,et al. Potent and Selective Inhibitors of the Inositol-requiring Enzyme 1 Endoribonuclease , 2011, The Journal of Biological Chemistry.
[51] Qiuyan Wang,et al. Inhibition of p97-dependent Protein Degradation by Eeyarestatin I* , 2008, Journal of Biological Chemistry.
[52] H. Fried,et al. Saccharomyces cerevisiae coordinates accumulation of yeast ribosomal proteins by modulating mRNA splicing, translational initiation, and protein turnover , 1985, Molecular and cellular biology.
[53] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[54] N. Dillon,et al. Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells , 2013, PLoS ONE.
[55] A. Zelenetz,et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] D. Piwnica-Worms,et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease , 2009, The Journal of cell biology.
[57] A. Goldberg,et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.
[58] Steven J Brown,et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways , 2011, Proceedings of the National Academy of Sciences.
[59] R. Millikan,et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] T. Libermann,et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[61] Tom Maniatis,et al. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.
[62] S. Soignet,et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] R. Bast,et al. Holland-Frei Cancer Medicine , 2016 .
[64] T. Hoppe,et al. Create and preserve: proteostasis in development and aging is governed by Cdc48/p97/VCP. , 2014, Biochimica et biophysica acta.
[65] P. Young,et al. A conserved unfoldase activity for the p97 AAA-ATPase in proteasomal degradation. , 2009, Journal of molecular biology.
[66] H. Handa,et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.
[67] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Yili Yang,et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. , 2007, Cancer research.
[69] L. Staudt,et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.
[70] A. Goldberg,et al. The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins , 2012, The EMBO journal.
[71] A. Goldberg,et al. Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97 , 2014, Current Biology.
[72] A. Amon,et al. Aneuploidy: cancer's fatal flaw? , 2009, Cancer research.
[73] R. Robinson,et al. 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97). , 2010, Bioorganic & medicinal chemistry letters.
[74] M. Yano,et al. Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] A. Eastman,et al. Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib , 2013, PloS one.
[76] K. Anderson,et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. , 2009, Blood.
[77] J. Hayes,et al. Transcription Factor Nrf1 Is Topologically Repartitioned across Membranes to Enable Target Gene Transactivation through Its Acidic Glucose-Responsive Domains , 2014, PloS one.
[78] M. Rolfe,et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.
[79] J. Chan,et al. Nrf1 Is Targeted to the Endoplasmic Reticulum Membrane by an N-terminal Transmembrane Domain , 2006, Journal of Biological Chemistry.
[80] M. Monden,et al. Expression Level of Valosin-Containing Protein (p97) Is Correlated With Progression and Prognosis of Non-Small-Cell Lung Carcinoma , 2004, Annals of Surgical Oncology.
[81] E. White,et al. Autophagy-Mediated Tumor Promotion , 2013, Cell.
[82] W. Wilson,et al. Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma , 2011, Clinical Cancer Research.
[83] A. Isacchi,et al. Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. , 2013, Journal of medicinal chemistry.
[84] D. Longo,et al. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. , 1998, The Journal of biological chemistry.
[85] M. Yano,et al. Expression Level of Valosin-Containing Protein (p97) Is Associated with Prognosis of Esophageal Carcinoma , 2004, Clinical Cancer Research.
[86] P. Richardson,et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. , 2014, Blood.
[87] Tina N. Davis,et al. In Vivo Pharmacodynamic Imaging of Proteasome Inhibition , 2009, Molecular imaging.
[88] R. Deshaies,et al. Quantitative Cell-based Protein Degradation Assays to Identify and Classify Drugs That Target the Ubiquitin-Proteasome System , 2011, The Journal of Biological Chemistry.
[89] R. Roden,et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. , 2013, Cancer cell.
[90] A. Goldberg,et al. Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.
[91] J. Keats,et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. , 2013, Cancer cell.
[92] D. Ron,et al. Structural Determinants of PERK Inhibitor Potency and Selectivity , 2010, Chemical biology & drug design.
[93] Brent M. Sanders,et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. , 2013, Cancer research.
[94] S. Demo,et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. , 2007, Cancer research.
[95] Maitreya J. Dunham,et al. Identification of Aneuploidy-Tolerating Mutations , 2010, Cell.
[96] N. Munshi,et al. NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.
[97] M. Dimopoulos,et al. Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. , 2014 .
[98] V. M. Malikov,et al. Vinca alkaloids , 2004, Chemistry of Natural Compounds.
[99] E. Krüger,et al. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. , 2010, Molecular cell.
[100] R. Deshaies,et al. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. , 2010, Molecular cell.
[101] Tom A. Rapoport,et al. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol , 2001, Nature.
[102] N. Munshi,et al. NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.
[103] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[104] M. Monden,et al. Valosin-Containing Protein (p97) and Ki-67 Expression Is a Useful Marker in Detecting Malignant Behavior of Pancreatic Endocrine Neoplasms , 2004, Oncology.
[105] R. Parker,et al. Eukaryotic Stress Granules Are Cleared by Autophagy and Cdc48/VCP Function , 2013, Cell.
[106] H. Jäck,et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. , 2007, Cancer research.
[107] L. Boise,et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. , 2006, Blood.
[108] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[109] Adam Frost,et al. A Ribosome-Bound Quality Control Complex Triggers Degradation of Nascent Peptides and Signals Translation Stress , 2012, Cell.
[110] Sara E. Miller,et al. Impaired Protein Aggregate Handling and Clearance Underlie the Pathogenesis of p97/VCP-associated Disease* , 2008, Journal of Biological Chemistry.
[111] D. Finley,et al. Recognition and processing of ubiquitin-protein conjugates by the proteasome. , 2009, Annual review of biochemistry.
[112] S. Alkan,et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. , 2001, British journal of haematology.
[113] K. Anderson,et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. , 2005, Cancer research.
[114] J R Yates,et al. Selective degradation of ubiquitinated Sic1 by purified 26S proteasome yields active S phase cyclin-Cdk. , 2001, Molecular cell.
[115] K. Young,et al. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma , 2008, Molecular Cancer.
[116] S. Alkan,et al. Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .
[117] Tom A. Rapoport,et al. Distinct Ubiquitin-Ligase Complexes Define Convergent Pathways for the Degradation of ER Proteins , 2006, Cell.
[118] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[119] S. Demo,et al. Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells , 2011, PloS one.
[120] Michael L. Wang,et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. , 2012, Blood.
[121] Wenzheng Zhang,et al. The p97-UFD1L-NPL4 Protein Complex Mediates Cytokine-Induced IκBα Proteolysis , 2013, Molecular and Cellular Biology.